PRODUCT INFORMATION

Pazopanib-d_6

Item No. 25446

CAS Registry No.:	1219592-01-4
Formal Name:	2-methyl-5-[[4-[methyl-d_3-[3-methyl-2-(methyl-d_3)-2H-indazol-6-yl]amino]-2-pyrimidinyl]amino]-benzenesulfonamide
MF:	$C_{21}H_{17}D_6N_7O_2S$
FW:	443.6
Chemical Purity:	≥98% (Pazopanib)
Deuterium Incorporation:	≥99% deuterated forms (d_1-d_6); ≤1% d_0
Supplied as:	A solid
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Pazopanib-d_6 is intended for use as an internal standard for the quantification of pazopanib (Item No. 12097) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated *versus* unlabeled).

Pazopanib-d_6 is supplied as a solid. A stock solution may be made by dissolving the pazopanib-d_6 in the solvent of choice, which should be purged with an inert gas. Pazopanib-d_6 is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of pazopanib-d_6 in these solvents is approximately 16 mg/ml.

Description

Pazopanib is a multi-kinase inhibitor that inhibits the VEGF receptors VEGFR1, VEGFR2, and VEGFR3 (IC_{50}s = 10, 30, and 47 nM, respectively, in a cell-free enzyme assay).[1] It also inhibits PDGFRα, PDGFRβ, and c-Kit (IC_{50}s = 71, 84, and 74 nM, respectively, in a cell-free enzyme assay) as well as additional receptor tyrosine kinases. Pazopanib inhibits upregulation of the surface adhesion proteins ICAM-1 and VCAM-1 induced by VEGF in multiple myeloma cells cocultured with human umbilical vein endothelial cells (HUVECs) and decreases multiple myeloma cell adhesion to HUVECs.[2] It also inhibits proliferation of multiple myeloma cells cocultured with HUVECs. Pazopanib (30 and 100 mg/kg) reduces tumor growth, induces apoptosis, decreases angiogenesis, and increases survival in a multiple myeloma mouse xenograft model. Formulations containing pazopanib have been used in the treatment of cancer.

References

1. Kumar, R., Knick, V.B., Rudolph, S.K., *et al.* Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. *Mol. Cancer Ther.* **6(7)**, 2012-2021 (2007).
2. Podar, K., Tonon, G., Satler, M., *et al.* The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. *Proc. Natl. Acad. Sci. USA* **103(5)**, 19478-19483 (2006).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM